Differential regulation of Cav3.2 and Cav2.2 calcium channels by CB1 receptors and cannabidiol
暂无分享,去创建一个
Erika K. Harding | T. Trang | G. Zamponi | I. A. Souza | M. Gandini | Sun Huang | Md Yousof Ali | V. M. Gadotti | Flavia T T Antunes
[1] J. Crippa,et al. Cannabidiol enhances the antinociceptive effects of morphine and attenuates opioid-induced tolerance in the chronic constriction injury model , 2022, Behavioural Brain Research.
[2] Christopher H George,et al. Planning experiments: Updated guidance on experimental design and analysis and their reporting III , 2022, British journal of pharmacology.
[3] Erika K. Harding,et al. Central and peripheral contributions of T-type calcium channels in pain , 2022, Molecular brain.
[4] M. Glass,et al. Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (CaV3) Inhibitors. , 2022, ACS chemical neuroscience.
[5] Xiaoqun Wang,et al. Structure, gating, and pharmacology of human CaV3.3 channel , 2022, Nature Communications.
[6] C. Bladen,et al. Inhibition of human recombinant T‐type calcium channels by phytocannabinoids in vitro , 2022, British journal of pharmacology.
[7] N. A. Caballero,et al. Theoretical Study of the Structural Stability, Chemical Reactivity, and Protein Interaction for NMP Compounds as Modulators of the Endocannabinoid System , 2022, Molecules.
[8] S. Ovchinnikov,et al. ColabFold: making protein folding accessible to all , 2022, Nature Methods.
[9] Zhuo Huang,et al. Closed-state inactivation and pore-blocker modulation mechanisms of human CaV2.2. , 2021, Cell reports.
[10] Stephen P. H. Alexander,et al. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors , 2021, British journal of pharmacology.
[11] Adam J Pawson,et al. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels , 2021, British journal of pharmacology.
[12] L. Dreyer,et al. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind placebo-controlled trial. , 2021, Pain.
[13] Jennifer A. Smith,et al. Cannabidiol activates neuronal Kv7 channels , 2021, bioRxiv.
[14] N. Yan,et al. Structure of human Cav2.2 channel blocked by the painkiller ziconotide , 2021, Nature.
[15] Y. de Koninck,et al. Sexual dimorphism in a neuronal mechanism of spinal hyperexcitability across rodent and human models of pathological pain , 2021, bioRxiv.
[16] Erika K. Harding,et al. The T‐type calcium channel antagonist, Z944, reduces spinal excitability and pain hypersensitivity , 2021, British journal of pharmacology.
[17] D. Finn,et al. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. , 2021, Pain.
[18] J. Mlost,et al. Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action , 2020, International journal of molecular sciences.
[19] Dennis J Sholler,et al. Therapeutic Efficacy of Cannabidiol (CBD): a Review of the Evidence From Clinical Trials and Human Laboratory Studies , 2020, Current Addiction Reports.
[20] Christopher H George,et al. ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020 , 2020, British journal of pharmacology.
[21] Ulrich Dirnagl,et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research* , 2020, BMC Veterinary Research.
[22] Esther J Pearl,et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research , 2020, PLoS biology.
[23] M. Rowbotham,et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. , 2020, Pain.
[24] Ying-Xian Pan,et al. Differential regulation of Cav2.2 channel exon 37 variants by alternatively spliced μ-opioid receptors , 2019, Molecular Brain.
[25] M. Huestis,et al. Cannabidiol Adverse Effects and Toxicity. , 2019, Current neuropharmacology.
[26] T. England,et al. A systematic review of cannabidiol dosing in clinical populations , 2019, British journal of clinical pharmacology.
[27] A. Moqrich,et al. Cav3.2 T-type calcium channels shape electrical firing in mouse Lamina II neurons , 2019, Scientific Reports.
[28] R. McLaughlin,et al. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain , 2018, Pain.
[29] O. Hogue,et al. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort , 2018, The journal of headache and pain.
[30] Christopher H George,et al. Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology , 2018, British journal of pharmacology.
[31] J. McDougall,et al. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis , 2017, Pain.
[32] R. Tallarida,et al. Single and combined effects of Δ9‐tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy‐induced neuropathic pain , 2017, British journal of pharmacology.
[33] F. Grotenhermen,et al. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies , 2017, Cannabis and cannabinoid research.
[34] J. Mogil,et al. Sex differences in neuroimmunity and pain , 2017, Journal of neuroscience research.
[35] D. Clauw,et al. Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. , 2016, The journal of pain : official journal of the American Pain Society.
[36] Gerald W. Zamponi,et al. Targeting voltage-gated calcium channels in neurological and psychiatric diseases , 2015, Nature Reviews Drug Discovery.
[37] R. Laprairie,et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor , 2015, British journal of pharmacology.
[38] Loren J. Martin,et al. Different immune cells mediate mechanical pain hypersensitivity in male and female mice , 2015, Nature Neuroscience.
[39] Penny F Whiting,et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. , 2015, JAMA.
[40] A. Moqrich,et al. The Low-Threshold Calcium Channel Cav3.2 Determines Low-Threshold Mechanoreceptor Function. , 2015, Cell reports.
[41] T. Pfeifer,et al. Small organic molecule disruptors of Cav3.2 - USP5 interactions reverse inflammatory and neuropathic pain , 2015, Molecular pain.
[42] C. Bladen,et al. Characterization of Novel Cannabinoid Based T-Type Calcium Channel Blockers with Analgesic Effects , 2014, ACS chemical neuroscience.
[43] G. Toney,et al. Activation of corticotropin-releasing factor receptors in the rostral ventrolateral medulla is required for glucose-induced sympathoexcitation. , 2014, American journal of physiology. Endocrinology and metabolism.
[44] M. Lee. Z944: A first in class T‐type calcium channel modulator for the treatment of pain , 2014, Journal of the peripheral nervous system : JPNS.
[45] C. Bladen,et al. The Deubiquitinating Enzyme USP5 Modulates Neuropathic and Inflammatory Pain by Enhancing Cav3.2 Channel Activity , 2014, Neuron.
[46] S. McAllister,et al. Cannabidiol inhibits paclitaxel‐induced neuropathic pain through 5‐HT1A receptors without diminishing nervous system function or chemotherapy efficacy , 2014, British journal of pharmacology.
[47] P. Diaz,et al. NMP-7 inhibits chronic inflammatory and neuropathic pain via block of Cav3.2 T-type calcium channels and activation of CB2 receptors , 2014, Molecular pain.
[48] Haitao You,et al. Analgesic effect of a mixed T-type channel inhibitor/CB2 receptor agonist , 2013, Molecular pain.
[49] R. W. Turner,et al. Signaling complexes of voltage-gated calcium channels , 2011, Channels.
[50] Haitao You,et al. Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands , 2011, Molecular pain.
[51] U. Meza,et al. Protein Kinase C-Mediated Inhibition of Recombinant T-Type CaV3.2 Channels by Neurokinin 1 Receptors , 2010, Molecular Pharmacology.
[52] Arthur J. Olson,et al. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..
[53] A. Eschalier,et al. T-Type Calcium Channel Inhibition Underlies the Analgesic Effects of the Endogenous Lipoamino Acids , 2009, The Journal of Neuroscience.
[54] P. Barrett,et al. Protein Kinase A Activity Controls the Regulation of T-type CaV3.2 Channels by Gβγ Dimers* , 2009, Journal of Biological Chemistry.
[55] G. Zamponi,et al. D2 dopamine receptors interact directly with N-type calcium channels and regulate channel surface expression levels , 2008, Channels.
[56] M. Connor,et al. Inhibition of Recombinant Human T-type Calcium Channels by Δ9-Tetrahydrocannabinol and Cannabidiol* , 2008, Journal of Biological Chemistry.
[57] R. Pertwee,et al. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond , 2008, Addiction biology.
[58] T. Soong,et al. Activation of Corticotropin-Releasing Factor Receptor 1 Selectively Inhibits CaV3.2 T-Type Calcium Channels , 2008, Molecular Pharmacology.
[59] B. MacVicar,et al. D1 Receptors Physically Interact with N-Type Calcium Channels to Regulate Channel Distribution and Dendritic Calcium Entry , 2008, Neuron.
[60] C. Altier,et al. Signaling complexes of voltage-gated calcium channels and G protein-coupled receptors. , 2008, Journal of receptor and signal transduction research.
[61] B. Spiegelman,et al. Direct G Protein Modulation of Cav2 Calcium Channels , 2006, Pharmacological Reviews.
[62] P. Barrett,et al. The molecular basis for T-type Ca2+ channel inhibition by G protein β2γ2 subunits , 2006, Proceedings of the National Academy of Sciences.
[63] A. Molleman,et al. Cannabinoid signalling. , 2006, Life sciences.
[64] M. De Waard,et al. How do G proteins directly control neuronal Ca2+ channel function? , 2005, Trends in pharmacological sciences.
[65] D. T. Yue,et al. G Protein-Gated Inhibitory Module of N-Type (CaV2.2) Ca2+ Channels , 2005, Neuron.
[66] Olivier Poirot,et al. Silencing of the Cav3.2 T‐type calcium channel gene in sensory neurons demonstrates its major role in nociception , 2005, The EMBO journal.
[67] H. Adams,et al. The medicinal use of cannabis in the UK: results of a nationwide survey , 2004, International journal of clinical practice.
[68] M. Huestis. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. , 2005, Handbook of experimental pharmacology.
[69] L. Petrocellis,et al. The endocannabinoid system and its therapeutic exploitation , 2004, Nature Reviews Drug Discovery.
[70] Aaron M. Beedle,et al. Modulation of High Voltage-Activated Calcium Channels by G Protein-Coupled Receptors , 2004 .
[71] Chien-Chang Chen,et al. Abnormal Coronary Function in Mice Deficient in α1H T-type Ca2+ Channels , 2003, Science.
[72] P. Barrett,et al. T-type calcium channel regulation by specific G-protein βγ subunits , 2003, Nature.
[73] Chien-Chang Chen,et al. Abnormal coronary function in mice deficient in alpha1H T-type Ca2+ channels. , 2003, Science.
[74] Franjo Grotenhermen,et al. Pharmacokinetics and Pharmacodynamics of Cannabinoids , 2003, Clinical pharmacokinetics.
[75] P. Lory,et al. Direct inhibition of T‐type calcium channels by the endogenous cannabinoid anandamide , 2001, The EMBO journal.
[76] J. Calixto,et al. Evidence for the participation of kinins in Freund's adjuvant-induced inflammatory and nociceptive responses in kinin B1 and B2 receptor knockout mice , 2001, Neuropharmacology.
[77] D. Ponde,et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide , 2001, British journal of pharmacology.
[78] K. Mackie,et al. Internalization and Recycling of the CB1 Cannabinoid Receptor , 1999, Journal of neurochemistry.
[79] K. Mackie,et al. Distinct Domains of the CB1 Cannabinoid Receptor Mediate Desensitization and Internalization , 1999, The Journal of Neuroscience.
[80] A. Basbaum,et al. Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates , 1998, Pain.
[81] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[82] D S Goodsell,et al. Automated docking of flexible ligands: Applications of autodock , 1996, Journal of molecular recognition : JMR.
[83] Asmar. Therapeutic Efficacy , 2020, Definitions.
[84] K. Mackie,et al. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[85] S. Hunskaar,et al. Formalin test in mice, a useful technique for evaluating mild analgesics , 1985, Journal of Neuroscience Methods.